Shaji Kumar, MD, Discusses 5-Year Overall Survival Data for MM Daratumumab Combo in the MAIA Study


At EHA 2021, Shaji Kumar, MD, reflects on the significance of 5-year data from the MAIA study of daratumumab plus lenalidomide/dexamethasone in patients with newly diagnosed multiple myeloma.

CancerNetwork® sat down with Shaji Kumar, MD, from the Mayo Clinic at the 2021 European Hematology Association (EHA) Congress to talk about overall survival for patients with transplant-ineligible newly diagnosed multiple myeloma who were treated with daratumumab (Darzalex) plus lenalidomide (Revlimid) and dexamethasone compared with lenalidomide and dexamethasone alone in the phase 3 MAIA trial (NCT02252172). At 5 years of follow-up, there was a significant reduction in the risk of death for patients taking both drug combinations.


This the first time that we have seen a difference in overall survival reported on this study. Obviously, with overall survival, we had to wait for much more mature data. With the current follow-up, what we see is that the 5-year overall survival [rates] for the daratumumab plus lenalidomide and dexamethasone was 66% compared with 53% for the lenalidomide and dexamethasone, which is, again, a significant improvement, or a 30% to 32% reduction in the risk of death when you use a 3-drug combination compared to the 2-drug combination.


Theirry F, Kumar S, Torben P, et al. Overall survival results with daratumumab, Lenalidomide, and dexamethasone versus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: phase 3 MAIA study. Presented at: 2021 European Hematology Association Annual Meeting; June 9-17, 2021; Virtual; Abstract LB1901. Accessed June 29, 2021.

Related Videos
Investigators must continue to explore the space for lisocabtagene maraleucel in mantle cell lymphoma, according to Manali Kamdar, MD.
Those with CML should discuss adverse effects such as nausea or fatigue with their providers to help optimize their quality of life during treatment.
A panel of 4 experts on multiple myeloma
A panel of 4 experts on multiple myeloma
Patients with CML can become an active part of their treatment plan by discussing any questions that come to mind with their providers.
A panel of 4 experts on multiple myeloma
Video 1 - 4 KOLs are featured in "Treating Patients Referred to Academic Centers for CAR T"
Video 1 - 4 KOLs are featured in "Identifying Potential Candidates for CAR T-Cell Therapy"
Beth Faiman, CNP, PhD, an expert on multiple myeloma
Jorge E. Cortes, MD, emphasizes proper communication between patients with chronic myeloid leukemia and their providers during the treatment course.
Related Content